Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors

Ashraf El-Dabh¹ and Deepak Acharya²
¹Guthrie Robert Packer Hospital, Sayre, USA; ²Division of Cardiovascular Disease, School of Medicine, University of Arizona, Tucson, USA

Abstract
Dasatinib and other tyrosine kinase inhibitors are commonly utilized in the management of chronic myelogenous leukemia. Pulmonary hypertension is an important adverse event associated with dasatinib. Mechanisms for pulmonary hypertension include pulmonary endothelial injury, apoptosis, and increased susceptibility to other triggers for pulmonary hypertension. The diagnosis is suspected based on symptoms, suggested by echocardiographic findings, and confirmed with right heart catheterization. Management includes discontinuation of dasatinib and initiation of pulmonary vasodilators. Persistent pulmonary hypertension is present in up to one third of patients after cessation of dasatinib. Other tyrosine kinase inhibitors, including bosutinib, lapatinib, and ponatinib have also been implicated in pulmonary hypertension in small series, although evidence for causation is less robust. A high index of suspicion, continued vigilance for pulmonary hypertension with long-term use, and early therapy are important in optimizing outcomes in this population.

Keywords
Right heart failure, pulmonary vasodilators, drug-induced pulmonary hypertension

Introduction
Pulmonary hypertension (PH)

PH is a disease of the pulmonary vasculature, which leads to right ventricular (RV) pressure overload, hypertrophy, dilation, and ultimately right heart failure if not recognized and adequately treated.¹,²

PH is classified into five subtypes. Group I (pulmonary arterial hypertension (PAH)) is characterized by morphological changes at the distal pulmonary arterial vasculature leading to increase in pulmonary vascular resistance. Group I includes idiopathic, heritable, drug-induced, toxin-induced PH, as well as PH associated with connective tissue disease, HIV infection, portal hypertension, congenital heart disease, and schistosomiasis. The majority of clinical trials of therapeutic agents in PH have studied Group I patients. Groups II–V PH is secondary to other conditions, such as left heart disease, chronic lung disease, thromboembolic disease and other pulmonary arterial obstructions, and other unclear and/or multifactorial mechanisms.

PH is usually suspected when a patient has dyspnea, exertional intolerance, signs of right heart failure, or syncope, in conjunction with an echocardiographic elevation in the RV systolic pressure and/or pulmonary artery systolic pressure over 40 mmHg. The definitive hemodynamic diagnosis of PAH is made with right heart catheterization (RHC). PAH has been defined as mean pulmonary artery pressure (mPAP) ≥ 25 mmHg at rest in the absence of elevated pulmonary capillary wedge pressure (PCWP) ≥ 15 mmHg and pulmonary vascular resistance (PVR) > 3 Woods Units (WU). The Sixth World Symposium on Pulmonary Hypertension (2018) proposed an updated hemodynamic definition of PH as mPAP > 20 mmHg, with associated PVR > 3 WU or greater required to diagnose precapillary PH.³ The treatment of PH is directed toward treating the underlying etiology.

Corresponding author:
Deepak Acharya, Division of Cardiovascular Disease, University of Arizona, 1501 N Campbell Avenue, Tucson, AZ 85711, USA.
Email: dacharya@shc.arizona.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
discontinuing offending agents, and initiating pulmonary vasodilators particularly in Group I, Group IV, and in selected patients with other etiologies of PH.\textsuperscript{1,2,8}

Currently commercially available pulmonary vasodilators have one of several mechanisms: phosphodiesterase inhibition, soluble guanylate cyclase stimulation, endothelin receptor antagonism, prostacyclin analogues, selective IP prostacyclin-receptor antagonism. Despite the rapid development of many drugs to treat PAH, patients are still diagnosed late, remain untreated, or inadequately treated. Survival has improved with modern combination therapies, and three-year survival is now in the 70% range, making it imperative to maintain a high index of suspicion and awareness of different agents associated with PH, since early diagnosis, withdrawal of the offending agent, and early treatment may help prevent irreversible RV failure and prolong survival.\textsuperscript{4,5}

**Dasatinib**

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used for treatment of newly diagnosed adults with Philadelphia chromosome positive (ph+) chronic myelogenous leukemia (CML) in chronic phase; or ph+ chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy. It was approved in the United States in November 2007 for treatment of chronic phase CML. Data suggest that dasatinib is associated with higher rate of cytogenic remission in imatinib-resistant patients and in chronic phase CML.\textsuperscript{6} In addition, dasatinib is currently being tested in other malignancies including melanoma, breast, lung, ovarian, and head and neck cancer.\textsuperscript{7} However, reports of PH in patients receiving dasatinib led to the 2015 European Society of Cardiology guidelines reporting a likely association of PH with dasatinib, defined as “a single-centre case – control study or multiple case series demonstrate an association or if clinical and haemodynamic recovery occurs after stopping exposure.”\textsuperscript{11} Based on accumulated evidence so far, the Sixth World Symposium on Pulmonary Hypertension (2018) has now classified the association of dasatinib with PH as definite.\textsuperscript{3}

**Epidemiology**

The first major population-based incidence was reported from the French PH registry. Among 2900 patients receiving dasatinib between 2006 and 2010, nine patients developed PH in the registry, and four additional cases of dasatinib-associated PH were reported to French regulatory agencies; therefore, the lowest estimate of PH in dasatinib-associated patients was 0.45%.\textsuperscript{6} In an updated report from the Bristol-Myers-Squibb (BMS) pharmacovigilance database of patients who received dasatinib between June 2006 and October 2013, 41 patients had PAH diagnosed by RHC. It was estimated that approximately 75,000 people had been prescribed dasatinib during that time period.\textsuperscript{8} In a pooled population of 2712 patients treated with dasatinib in 11 clinical trials, six (0.2%) were found to have PH.\textsuperscript{8} A phase 3 study of 670 patients on dasatinib followed for seven years, reported incidence of any PH as diagnosed by invasive and noninvasive tests at 2.4% (16 patients). Only one case of PAH confirmed by RHC was reported, suggesting that not all patients suspected of having PH were being assessed with a RHC to document PAH.\textsuperscript{9} A study of 212 patients at 17 Australian institutions reported a 5% incidence of PH as measured by echocardiogram.\textsuperscript{10} A phase II trial of 113 children with CML treated with dasatinib and followed for a median of 48.4 months found no cases of PH.\textsuperscript{11}

The true incidence and prevalence of PAH in association with dasatinib has been challenging to estimate because (1) many of the studies in the published literature are case reports or series that do not report the total number of patients receiving dasatinib at those institutions during that time period; (2) large-scale formal echocardiographic screening studies for asymptomatic PH have not been performed; (3) suspected cases have not uniformly been confirmed with catheterization; and (4) symptoms of PH may overlap with other, more common, complications of dasatinib, such as pleural effusions. Despite these limitations, based on available estimates, PH appears to be an important complication of dasatinib.

**Pathogenesis**

Dasatinib, imatinib, nilotinib, bosutinib, lapatinib, and ponatinib are commonly used TKIs. Different drugs have different potencies and effects on breakpoint cluster region-Abelson leukemia (BCR-ABL). These drugs target not only BCR-ABL but several other molecules including c-ABL, c-KIT, platelet-derived growth factor receptor, and SRC-tyrosine kinase. It is thought to be the varying specificities of the different drugs for these additional targets that are responsible for the differential association of PH with some TKIs, in particular dasatinib. Proteomic analysis of imatinib, nilotinib, and dasatinib revealed that dasatinib bound over 30 tyrosine and serine/threonine kinases, substantially more than imatinib and nilotinib. Furthermore, there were important differences in the interaction profiles of the three drugs.\textsuperscript{12} SRC kinases are important in vascular regulation, including vasodilation and vascular proliferation,\textsuperscript{6,13,14} and SRC inhibition has been postulated to lead to pulmonary vascular dysregulation and PH in association with dasatinib.\textsuperscript{15} However, recent data suggest that at least some pathways of PH associated with dasatinib may be independent of SRC inhibition.\textsuperscript{16} It is also important to note, however, that most patients diagnosed with PH on dasatinib had received other chemotherapeutic agents, which along with the underlying myeloproliferative disease, could lead to some confounding of dasatinib effects.

An important study by Guignabert and colleagues highlights several pathophysiologic findings. In rats,
pretreatment by dasatinib by itself did not lead to PH, but led to an exaggerated response to monocrotaline and chronic hypoxia. Dasatinib increased markers of endothelial dysfunction including soluble ICAM-1, soluble VCAM-1, and soluble E selectin; attenuated hypoxic vasoconstriction; and induced pathways implicated in endoplasmic reticulum stress in rats. In cultured human pulmonary endothelial cells, dasatinib induced apoptosis in a dose-dependent manner, and the mechanism was likely related to mitochondrial reactive oxygen species and independent of its action on Src family kinases. Finally, humans treated with CML treated with dasatinib had higher levels of sICAM-1, sVCAM-1, and sE-selectin compared to those treated with imatinib suggesting endothelial toxicity. The authors conclude that dasatinib causes endothelial toxicity, and while it may not necessarily cause PH by itself, increases susceptibility to PH in conjunction with other factors.16

A study on a rat model found that dasatinib increased pulmonary arterial pressure, and that the Rho-kinase inhibitor Y27632 partially reversed the changes in vitro and ex vivo, and co-administration of Y27632 blunted the increased pulmonary response to dasatinib, suggesting potential targets for intervention.17

A recent study utilizing the World Health Organization pharmacovigilance database evaluated 28 protein kinase inhibitors and found that dasatinib, bosutinib, ponatinib, ruxolitinib, and nilotinib displayed pharmacovigilance signals for association with PAH. When these pharmacological signals were correlated with the affinity for different targets of interest, the signals were associated with four nonreceptor protein kinases belonging to Src protein kinase pathway (c-Src, c-Yes, Lck, Lyn) as well as TEC. Furthermore, the dasatinib affinity profile for protein kinases implicated in PAH was unique.18

Early reports suggested that dasatinib-related PAH may be reversible upon discontinuation of dasatinib. However, more recent data suggest that PAH may persist in over one third of patients despite dasatinib discontinuation.19 Daccord and colleagues reported on pathologic findings on explanted lungs of a patient with CML who developed PAH on dasatinib, which worsened on nilotinib despite vasodilator therapy and required lung transplantation. They observed typical lesions of chronic PAH, including medial hypertrophy, concentric laminar intimal thickening, and plexiform lesions.20 These findings of chronic and potentially nonreversible findings support the recommendation of close long-term follow-up for persistent/worsening clinical disease.

**Clinical manifestations**

Common symptoms of PH are shortness of breath and exertional intolerance. Patients with dasatinib commonly (up to 35%) develop pleural effusions, which is not related to PH, but clinical symptoms of pleural effusion such as dyspnea overlap with those of PH.6,21 However, findings of peripheral edema, jugular venous distension, congestive hepatopathy, RV heave, or enlargement should raise suspicion for PH rather than effusion alone. Pleural effusions and PH may occur individually, concurrently, or sequentially. Most patients who have pleural effusion do not have PH. However, a high index of suspicion for PH should be maintained, particularly in patients who do not improve with drug dose reduction or thoracentesis.22,23 Most reported cases of PH presented with shortness of breath, exertional intolerance/fatigue, and fluid retention.

The timing of development of PAH after initiation of dasatinib is not predictable. Shah and colleagues reviewed 41 cases of RHC-confirmed PAH in dasatinib treated patients from the BMS pharmacovigilance database. Patients presented with PAH at a median duration of 31.5 months after dasatinib initiation, with a wide range from 1 week to 75 months.8 In a French PH registry, the median time between initiation of dasatinib and diagnosis of PAH was 42 months.19 Therefore, a high index of suspicion should be maintained while patients are receiving dasatinib regardless of how long they have been on it.

**Evaluation**

In the context of appropriate symptoms, an echocardiogram is the initial screening test. Elevated pulmonary pressure is usually detected using tricuspid regurgitation velocity by Doppler. Ancillary findings of RV hypertrophy or enlargement, right atrial enlargement, RV dysfunction, and septal deviation to the left provide supporting evidence of PH. A patient with completely normal echocardiogram is unlikely to have severe PH. However, it is important to emphasize that patients with severe PH and failed right ventricle may not be able to generate a high pulmonary artery pressure, so management decisions should not be made solely using estimated PA pressures by echocardiogram. In patients with clinical and echocardiographic suspicion of PH, a RHC is mandatory to evaluate pulmonary artery pressures, left sided filling pressures, and RV function, and serves as a baseline to assess response to discontinuation of dasatinib or addition of pulmonary vasodilators. Other variables with known prognostic value in PH, such as 6 minute walk test, brain natriuretic peptide (BNP), and World Health Organization functional class, can also be measured.

Once PAH is diagnosed, potential causative or risk factors other than dasatinib should be also excluded. These include autoimmune diseases, pulmonary thromboembolism, parenchymal lung disease, other drugs or toxins associated with PAH, sleep apnea, liver disease, and the underlying myeloproliferative disease itself.1

In asymptomatic patients, data are insufficient to recommend routine periodic screening echocardiograms to detect occult PH.

**Management**

Once a diagnosis of dasatinib-induced PAH is made, dasatinib should be permanently discontinued, as per guidelines.
from the Food and Drug Administration and the manufac-
turer.24,25 This is imperative, since the majority of published
studies have reported that the PAH may be at least partially
reversible after discontinuation of drug. Dose reduction
alone is inadequate, since PAH may not improve, and in
fact may progress despite dasatinib dose reduction.22,26
Furthermore, patients may not respond to pulmonary vaso-
dilators if dasatinib is continued.27 Finally, if pulmonary
pressures normalize after dasatinib discontinuation, patients
should not be rechallenged with dasatinib.

The question of whether dasatinib discontinuation alone
is sufficient or when specific pulmonary vasodilators are
necessary has not been conclusively answered. In the initial
report of nine cases from the French PH registry, two
patients were treated with endothelin receptor antagonists,
one with calcium channel blocker, and six were not treated
with any pulmonary vasodilator. Among these patients,
eight showed significant hemodynamic and clinical improve-
ments after dasatinib discontinuation, but none showed
complete normalization, and two died during follow-up
(one from sepsis and one after a long-distance plane
flight).6 In an updated analysis of 21 patients with RHC-
confirmed PAH from the French PH registry, all patients
had dasatinib discontinued, and 11 had PAH medications
prescribed. Mean PA pressure decreased from 45 to
26 mmHg on follow-up. However, at four months, seven
patients had persistent PAH by RHC. Of these seven, four
normalized their PVR on long-term follow-up.19 In the
BMS pharmacovigilance report, follow-up data were avail-
able for 36 patients, of whom 21 had complete resolution of
PAH and 15 had partial resolution.8 Details of pulmonary
vasodilator use were not reported. In a retrospective analysis
of 138 patients on dasatinib, 48 had pleural effusions, of
which 18 had echocardiograms with elevated pulmonary
pressure. Discontinuation of dasatinib led to normalization
of PA pressure in 10 patients.21 Although initially thought
to be a largely reversible process, recent pathophysiologic
evidence and follow-up studies suggest persistence in a sub-
stantial minority of cases, and it would seem reasonable to
initiate pulmonary vasodilators concurrent with dasatinib
cessation, particularly in symptomatic patients or those
with severe PAH and/or RV failure. If pulmonary pressure
and RV function subsequently normalizes, decisions regard-
ing discontinuation of pulmonary vasodilators should be
made in a center with experience treating PH under close
monitoring. Successful weaning of vasodilators after nor-
malization of PA pressures has been reported.15,28 Some
investigators have developed treatment algorithms to
decide on vasodilator use, but note lack of strong evidence,
and there are no formal society guidelines at this time.19

Based on currently available data, no recommendations
can be made regarding choice of specific pulmonary vaso-
dilator. The majority of cases that noted the specific vaso-
dilator utilized sildenafil, a few used bosentan, and one
reported calcium channel blocker use. The role of the
newer pulmonary vasodilators or initial combined
vasodilator therapy has not been clearly defined. Vasodilator adjustment according to existing standard PH
guidelines is most likely the best approach.

It is also important to ensure that the underlying mye-
lloproliferative disorder is treated, since myeloproliferative
disease itself can lead to PH. Imatinib remains the first line
treatment for CML. In patients whose resistance or
intolerance to imatinib was the reason for institution of
dasatinib, nilotinib has been commonly used and generally
well tolerated.15,23,29,30 Nilotinib has a similar safety pro-
file to imatinib, likely related to more limited molecular
targets compared to dasatinib12 (see ‘‘PH and other TKIs’’
section).

Prognosis

The relatively higher resolution rate with discontinuation
suggests a better prognosis than comparable incident idio-
pathic PAH. Among the 41 cases with dasatinib-related
PAH in the BMS pharmacovigilance registry which included
the nine patients initially reported in the French registry,
there were three deaths: one due to progression of AML,
one due to candidemia sepsis with concomitant residual
PAH and CHF (where the RV dysfunction could have con-
tributed to the poor prognosis), and one after a long-dis-
tance flight. The first reported death directly attributable to
PAH was a 36-year-old woman who presented with severe
dyspnea 34 months after dasatinib initiation and was diag-
nosed with PAH by RHC. She deteriorated on sildenafil and
catecholamines, and had a cardiac arrest four days after
presentation.31 Despite the low reported mortality rate, it
is not known in the general population how many patients
on dasatinib experienced sudden death from RV failure or
arrhythmias without PAH ever having been diagnosed.
Therefore, vigilance to potential early signs and symptoms
of PH, and prompt discontinuation of dasatinib before the
PAH is advanced is necessary.

PH and other TKIs

TKIs, primarily imatinib, have been extensively evaluated in
PH. In vitro studies implicated platelet-derived growth fac-
tors in the pathophysiology of PH.32,33 Imatinib, a BCR-
ABL inhibitor, also inhibited PDGF-R. In animal models,
imatinib reversed PH caused by monocrotaline or chronic
hypoxia.34 This led to several small human studies, and
ultimately the Imatinib in PAH, a Randomized Efficacy
Study trial in which patients with PH who were sympto-
matic on two or more vasodilators were randomized to ima-
tinib versus placebo. Imatinib led to an increase in six-
minute walk distance by 32 m, a decrease in PVR of
379 d.s.cm−5, and increased cardiac output by 0.881/min.
However, time to clinical worsening was no different
between the groups, and there was a high rate of adverse
events, including subdural hematomas, in the imatinib
group. Therefore, while pathophysiologic improvements
were seen, the authors note that the drug can have pleiotropic effects with deleterious consequences.\textsuperscript{35} In contrast to the potentially salutary effects of imatinib, several TKIs other than dasatinib have been implicated in PH, although the numbers are small and the associations sometimes confounded. In a single-center study of 27 patients treated with lapatinib, six were found to have pulmonary artery hypertension, defined as PASP $>50$ mmHg by echocardiogram. Three had confirmatory RHC, and all three normalized their PA pressures after lapatinib discontinuation.\textsuperscript{36} Other case reports have described patients who initially had dasatinib-induced PAH with initial improvement after dasatinib discontinuation who again had clinical worsening and severe PAH by RHC after they were switched to bosutinib.\textsuperscript{37,38} Quilot and colleagues report a worsening and severe PAH by RHC after they were initially had dasatinib-induced PAH with initial improvement from nilotinib to bosutinib with severe deterioration requiring parenteral prostaglandin therapy, which improved after bosutinib initiation, with severe PAH on repeat RHC. He was stabilized clinically with ambrisentan and sildenafil RHC was not reported. He had clinical worsening after being transitioned to ponatinib. Ponatinib was stopped and she was initiated on sildenafil and ambrisentan with clinical improvement. RHC 10 months after discontinuation showed mild PH (mPAP 30 mmHg).\textsuperscript{39} A 72-year-old man with hypertension and evidence of mild left ventricular dilation and diastolic dysfunction had worsening dyspnea and elevated BNP levels after nilotinib initiation, in conjunction with elevated PA pressure by echo. Symptoms improved after diuresis and nilotinib discontinuation. No RHC was performed.\textsuperscript{40} A trial evaluating nilotinib as a therapy for PH was terminated early because of high incidence of adverse events.\textsuperscript{41} Another patient with dasatinib-related severe PAH had clinical improvement with sildenafil, although post-sildenafil RHC was not reported. He had clinical worsening after nilotinib was initiated, with severe PAH on repeat RHC. He was stabilized clinically with ambrisentan and tadalafil. Because of loss of CML response, he was switched from nilotinib to bosutinib with severe deterioration requiring parenteral prostaglandin therapy, which improved after bosutinib discontinuation. He subsequently was started on ponatinib and again had clinical worsening.\textsuperscript{42} This challenging case illustrates the difficulty in attributing PAH to a particular agent given the complex clinical course.

A comparative analysis of 105 patients with CML treated with dasatinib, nilotinib, or imatinib evaluated PA pressures by echocardiogram and a peak tricuspid regurgitation velocity gradient of 31 mmHg or higher was considered “possible PH.” With this measure, 2.7% of patients on imatinib, 10% on nilotinib, and 13.2% on dasatinib met criteria for PH.\textsuperscript{43} Given the liberal diagnostic criteria and lack of RHC confirmation, this criterion may significantly overestimate the incidence of PH, but underscores the fact that early subclinical PH may be more prevalent than previously appreciated.

**Conclusions**

In general, PH is a treatable but not curable disease, and frequently progresses despite medical therapy. Even with the many currently available drugs, morbidity and mortality remain high. The high rate of reversibility of dasatinib-induced PAH in contrast to many other causes of PAH is intriguing. The mechanisms behind the reversibility or lack of reversibility of dasatinib-induced PAH are not clear. However, further study of these pathways may provide important information into the pathophysiology of PAH in other populations, and potentially new targets to combat this serious condition.

**Authors’ contribution**

AE-D: inception, planning, literature review, draft manuscript, revision. DA: planning, manuscript writing, revision, supervision.

**Conflict of interest**

The author(s) declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iD**

Deepak Acharya  
[https://orcid.org/0000-0002-9635-0798](https://orcid.org/0000-0002-9635-0798)

**References**

1. Authors/Task Force M, Galie N, Humbert M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPc), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2015; 37(1): 67–119.

2. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62: D34–D41.

3. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019; 53(1).

4. Gall H, Felix JF, Schneck FK, et al. The Giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups. *J Heart Lung Transplant* 2017; 36; 957–967.

5. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. *Chest* 2012; 142: 448–456.

6. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation* 2012; 125: 2128–2137.

7. US National Library of medicine clinicaltrials.gov search. [https://http://www.clinicaltrials.gov/ct2/results?term=dasatinib&Search=Apply&v=and&gndr=&type=&rslt=](https://http://www.clinicaltrials.gov/ct2/results?term=dasatinib&Search=Apply&v=and&gndr=&type=&rslt=) (accessed 13 April 2019).

8. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. *Am J Hematol* 2015; 90: 1060–1064.

9. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia
patients: 7-year follow-up of study CA180-034. *Am J Hematol* 2016; 91: 869–874.

10. Fox LC, Cummins KD, Costello B, et al. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. *Blood Adv* 2017; 1: 802–811.

11. Gore L, Kearns PR, de Martino ML, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. *J Clin Oncol* 2018; 36: 1330–1338.

12. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. *Blood* 2007; 110: 4055–4063.

13. Guignabert C and Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. *Eur Respir J* 2013; 41: 3–4.

14. Rosenkranz S, Ikuno Y, Leong FL, et al. Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. *J Biol Chem* 2000; 275: 9620–9627.

15. Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. *Eur Respir J* 2011; 38: 218–220.

16. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. *J Clin Invest* 2016; 126: 3207–3218.

17. Fazakas C, Nagaraj C, Zabin D, et al. Rho-kinase inhibition ameliorates dasatinib-induced endothelial dysfunction and pulmonary hypertension. *Front Physiol* 2018; 9: 537.

18. Cornet L, Khouri C, Roustit M, et al. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. *Eur Respir J* 2019; 53(5).

19. Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. *Eur Respir J* 2017; 50(1).

20. Daccord C, Letovance I, Yerly P, et al. First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. *Eur Respir J* 2018; 51(3).

21. Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. *J Clin Oncol* 2007; 25: 3908–3914.

22. Sano M, Saotome M, Urushida T, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia-critical alert. *Intern Med* 2012; 51: 2337–2340.

23. Orlandi EM, Rocca B, Pazzano AS, et al. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukemia. *Leuk Res* 2012; 36: e4–e6.

24. Administration Food and Drug. *FDA drug safety communication: sprycel (dasatinib) and risk of pulmonary arterial hypertension*, 2011. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-sprycel-dasatinib-and-risk-pulmonary-arterial-hypertension. (accessed 13 April 2019).

25. Dasatinib prescribing label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s788lbl.pdf. (accessed 13 April 2019).

26. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. *Bone Marrow Transplant* 2009; 43: 967–968.

27. Groeneveldt JA, Gans SJ, Bogaard HJ, et al. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. *Eur Respir J* 2013; 42: 869–870.

28. Bachelli Ramirez HL, Alvarez Alvarez CM, Rodriguez Reguero JJ, et al. Reversible pre-capillary pulmonary hypertension due to dasatinib. *Respir Care* 2014; 59: e77–e80.

29. Rasheed W, Flaim B and Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. *Leuk Res* 2009; 33: 861–864.

30. Swords R, Mahalingam D, Padmanabhan S, et al. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. *Drug Des Devel Ther* 2009; 3: 89–101.

31. Morishita S, Hagihara M, Itabashi M, et al. Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia. *Rinsho Ketsueki* 2015; 57: 999–1003.

32. Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2008; 178: 81–88.

33. Humbert M, Monti G, Fastoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. *Eur Respir J* 1998; 11: 554–559.

34. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. *J Clin Invest* 2005; 115: 2811–2821.

35. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. *Circulation* 2013; 127: 1128–1138.

36. Alkhatib Y, Albashaireh D, Al-Aqtash T, et al. The role of tyrosine kinase inhibitor “Lapatinib” in pulmonary hypertension. *Palm Pharmacol Ther* 2016; 37: 81–84.

37. Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. *Eur Respir J* 2016; 48: 1517–1519.

38. Seegobin K, Babbar A, Ferreira J, et al. A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib. *Pulm Circ* 2017; 7: 808–812.

39. Quilot FM, Georges M, Favrot N, et al. Pulmonary hypertension associated with ponatinib therapy. *Eur Respir J* 2016; 47: 676–679.

40. Zakrzewski D, Sefersyna I, Warzocha K, et al. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. *Int J Hematol* 2012; 96: 132–135.

41. Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH). https://clinicaltrials.gov/ct2/show/NCT01179737. (accessed 13 April 2019).

42. Hickey PM, Thompson AA, Charalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. *Eur Respir J* 2016; 48: 1514–1516.

43. Minami M, Arita T, Iwasaki H, et al. Comparative analysis of PK profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. *Blood* 2009; 33: 861–864.